Myeloma and Related Diseases Registry (MRDR)

COVID-19 NOTICE: the MRDR team continues operations working from home and can be contacted by email and phone for any queries and support we can provide to sites. We recognise the pandemic may affect research and appreciate any contributions possible during this time. Our best wishes to all site staff and patients participating in the registry.

Find out more

This clinical quality registry aims to improve myeloma outcomes by providing an evidence base for the best strategies to diagnose, treat and support people with myeloma and related diseases.

What is the registry?

Learn about how the registry works and the data we collect.
Benefits

Participation in the registry provides advantages for sites and patients.
About our projects

Find out about MRDR projects and how registry data is being used.
3625

Patients accrued

2382

Patients with multiple myeloma

46

Number of approved sites

424

Biobank participants

Latest news

My-PROMPT trial published!
05 Apr 2020

Real-time feedback of patient-reported outcomes feasible for patients and clinicians!

Read more
COVID-19 NOTICE
20 Mar 2020

MRDR still operating during COVID-19 pandemic.

Read more
Myeloma 1000 Biobank reaches 400+ samples
03 Feb 2020

The Myeloma 1000 Biobank now has samples from over 400 patients!

Read more
First patient for FRAIL-M trial
26 Nov 2019

FRAIL-M, a trial using MRDR infrastructure, has commenced recruitment.

Read more

Participating organisations